HOME >> MEDICINE >> NEWS
CT colonography versus colonoscopy for colorectal cancer

Colorectal cancer is the second leading cause of cancer deaths in most developed countries. Screening for colorectal malignancies and polyps (which frequently become cancerous) has been shown to lower the number of deaths from cancer. Most cancer societies and preventive task forces recommend regular screening for cancer of the colon.

Physicians often recommend colonoscopy for screening. Unfortunately, this procedure is uncomfortable and occasionally results in perforation of the colon, sometimes leading to death.

CT colonography is a relatively new imaging technology that can be used to examine the large bowel and rectum where these cancers occur. It is a noninvasive technique that reveals cancer lesions and polyps with nearly the same sensitivity and specificity as colonoscopy, without the risks of bowel perforation.

This study by Heitman and colleagues compares the costs and effectiveness of these two approaches to screening, using assumed prevalences of polyps and cancers among average-risk individuals 50 to 74 years of age. They found that screening 100 000 patients with CT colonography would cost $2.3 million more (in Canadian dollars) than with colonoscopy, and would avoid 3.8 fatal perforations -- but at the same time, this method would lead to 4.1 cancer-related deaths from polyps not seen with CT, which would later become malignant. (Colonoscopy is slightly more sensitive than CT colonography, and could be expected to detect a certain number of polyps that the CT method would miss.)

New technologies are always attractive. Because CT colonography does not physically invade the body, it has even more appeal -- it is easier for patients to accept. Its cost, however, is much higher, and its benefit (in terms of years of living that are gained) is only slightly lower than when colonoscopy is used.


'"/>

Contact: Dr. Joseph Romagnuolo
romagnuo@musc.edu
Canadian Medical Association Journal
10-Oct-2005


Page: 1

Related medicine news :

1. CT colonography even safer than previously reported, says study
2. CT colonography excellent for colorectal cancer screening
3. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
4. Quality versus quantity -- transforming kidney transplant policy
5. Fixed versus growth intelligence mindsets: Its all in your head, Dweck says
6. Mechanism of black cohosh versus hot flashes revealed
7. IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects
8. Adolescent condom use with casual versus main partners
9. Serendipity versus planning - cancer drugs of the future?
10. Study shows rituximab effective in treating chronic graft-versus-host disease
11. Gap widens between optimal versus actual cholesterol levels

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: colonography versus colonoscopy for colorectal cancer

(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
Cached News: